Clinical Trials: Chain of Custody Documentation

Case Studies on Essential Elements of Chain of Custody Logs and CAPA Solutions

Posted on digi By digi

Chain of custody (CoC) documentation is essential for maintaining the integrity and traceability of biological samples in clinical trials. A well-maintained CoC log ensures every handover—from collection at the clinical site to arrival at the testing laboratory—is documented and compliant with regulatory expectations. Agencies like the FDA, EMA, and ICH emphasize the importance of CoC as a cornerstone of Good Clinical Practice (GCP) and data integrity.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

How to Achieve Maintaining Data Integrity in Sample Transfers with FDA/EMA Oversight

Posted on digi By digi

Maintaining data integrity during clinical sample transfers is a regulatory imperative. Whether moving biological specimens between sites, labs, or third-party vendors, every handover must be documented, secure, and traceable. The FDA and EMA both expect that all data related to the transfer, condition, and custody of clinical samples uphold ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available).

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

Digital Chain of Custody Tools – CAPA Solutions

Posted on digi By digi

The digitalization of chain of custody (CoC) documentation has become a key strategy in enhancing sample traceability and regulatory compliance in clinical trials. Traditional paper-based CoC logs are prone to human error, illegible entries, delayed access, and audit limitations. Regulatory authorities such as the FDA and EMA are increasingly favoring digital tools that enable real-time tracking, electronic signatures, and secure audit trails.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

Case Studies on Audit Trails for Sample Movement and CAPA Solutions

Posted on digi By digi

An audit trail is the documented and verifiable path that samples follow throughout their lifecycle—from collection and storage to shipment and analysis. In clinical trials, where biological samples directly inform safety, efficacy, and pharmacokinetic conclusions, regulatory agencies demand transparent and tamper-proof tracking. Any break in this trail can cast doubt on data reliability and lead to compliance findings.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

Case Studies on Audit Trails for Sample Movement and CAPA Solutions

Posted on digi By digi

The chain of custody in clinical trials is a regulatory backbone that ensures biological samples are traceable from the point of collection to the final analysis. This trail of documentation is more than a formality—it’s essential for data integrity, subject safety, and inspection readiness. When samples move across clinical sites, couriers, biorepositories, and central laboratories, every handover must be documented with precision to meet FDA, EMA, and ICH GCP expectations.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

Role of Investigators in Sample Custody – CAPA Solutions

Posted on digi By digi

In a clinical trial, while the sponsor retains overall responsibility for study conduct, investigators play a pivotal role in safeguarding the integrity of biological samples collected at their sites. The accurate tracking, documentation, and transfer of these samples directly impact the validity of trial data. Any deviation in the sample custody chain can raise concerns about Good Clinical Practice (GCP) compliance, data integrity, and subject safety.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

Cross-Border Sample Transfers and Documentation – Regulatory Compliance Playbook

Posted on digi By digi

Cross-border movement of clinical trial samples involves a complex interplay of regulatory, logistical, and documentation requirements. Biological samples such as blood, plasma, serum, DNA, and tissue are frequently shipped from clinical trial sites to central laboratories located in different countries or regions for specialized testing. While this practice enables global scalability and cost-efficiency, it also introduces regulatory risks associated with customs, documentation, biosafety classification, and chain of custody.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

Building Responsibilities of Couriers and Labs for Regulatory Compliance

Posted on digi By digi

While clinical investigators and site staff are responsible for the initial collection and custody of trial samples, the integrity of those samples depends equally on downstream stakeholders—namely, the couriers who transport them and the laboratories that receive and analyze them. Maintaining regulatory compliance during this transition requires precise role definitions, validated handover procedures, and documented accountability from point of collection to final analysis.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

Handling Discrepancies in Custody Logs – Global Oversight Strategies

Posted on digi By digi

The chain of custody (CoC) documentation is a vital component of clinical trial sample integrity, serving as the formal record of transfer from one responsible party to another. When custody logs are incomplete, inconsistent, or incorrect, it raises critical data integrity concerns with regulatory agencies. Discrepancies in logs can indicate poor documentation practices, lack of oversight, or even potential misconduct.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management

How to Achieve Electronic Signatures in Sample Handover with FDA/EMA Oversight

Posted on digi By digi

With the growing reliance on decentralized and remote clinical trials, paper-based chain of custody (CoC) logs are increasingly being replaced by electronic systems. One of the most critical aspects of this digital transformation is ensuring that electronic signatures used in clinical sample handovers meet regulatory expectations.

Click to read the full article.

Chain of Custody Documentation, Laboratory and Sample Management